Carnegie acted as joint bookrunner in the SEK 314 million rights issue in Oncopeptides.
Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.
Carnegie acted as joint bookrunner in the SEK 314 million rights issue in Oncopeptides.
Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.